ArticleScientific reports2016
Expression of osteoprotegerin and its ligands, RANKL and TRAIL, in rheumatoid arthritis.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Circulating osteoprotegerin levels are elevated in rheumatoid arthritis: a systematic review and meta-analysis.Clinical rheumatology · 2017Pooled it
- The Liver-Heart Axis in Rheumatoid Arthritis: Associations of Liver Fibrosis, Organokines, Endothelin-1, and Cardiovascular Risk.International journal of molecular sciences · 2026Article
- Article
- Review
- Osteopontin, osteoprotegerin and musculoskeletal ultrasound findings in first-degree relatives of rheumatoid arthritis: potential markers of preclinical disease.BMC musculoskeletal disorders · 2024Article
- Fractionated whole body γ-irradiation aggravates arthritic severity via boosting NLRP3 and RANKL expression in adjuvant-induced arthritis model: the mitigative potential of ebselen.Inflammopharmacology · 2023Article
- The association of serum RANKL levels with disease activity and hematological parameters in Syrian patients with rheumatoid arthritis.Biochemistry and biophysics reports · 2022Article
- Organokines in Rheumatoid Arthritis: A Critical Review.International journal of molecular sciences · 2022Review
- Assessment of bone metabolism biomarkers in serum and saliva of cirrhotic patients.Clinical oral investigations · 2022Article
- The role of NK cells in rheumatoid arthritis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2021Review
- Article
- Large cavernous carotid artery aneurysm with spontaneous thrombosis: is there more to a change in morphology than there seems to be? Illustrative case.Journal of neurosurgery. Case lessons · 2021Article
- Cannabinoid-based therapy as a future for joint degeneration. Focus on the role of CBPharmacological reports : PR · 2021Review
- Total Saponins fromBioMed research international · 2021Article
- Synovial fibroblast-derived exosomal microRNA-106b suppresses chondrocyte proliferation and migration in rheumatoid arthritis via down-regulation of PDK4.Journal of molecular medicine (Berlin, Germany) · 2020Article
- Comparison of RANKL expression, inflammatory markers, and cardiovascular risk in patients with acute coronary syndrome with and without rheumatoid arthritis.Rheumatology international · 2019Article
- Gene expression analysis of vascular pathophysiology related to anti-TNF treatment in rheumatoid arthritis.Arthritis research & therapy · 2019Article
- miR-145-5p Increases Osteoclast Numbers In Vitro and Aggravates Bone Erosion in Collagen-Induced Arthritis by Targeting Osteoprotegerin.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- Cross-talk between primary osteocytes and bone marrow macrophages for osteoclastogenesis upon collagen treatment.Scientific reports · 2018Article
- Protein tyrosine phosphatase non-receptor 22 and C-Src tyrosine kinase genes are down-regulated in patients with rheumatoid arthritis.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoprotegerin (OPG), receptor activator of nuclear factor-ΚB ligand (RANKL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) have been involved in rheumatoid arthritis (RA) pathophysiology. In this study, we assessed messenger RNA (mRNA) expression of these molecules by qPCR in peripheral blood from 26 patients with RA (12 of them with ischemic heart disease -IHD) and 10 healthy controls. Correlation coefficients between OPG, RANKL and TRAIL expression levels in RA patients and their clinical and demographic characteristics were also evaluated. Whereas OPG and OPG/TRAIL ratio expression were significantly increased in RA patients compared to controls (fold change = 1.79, p = 0.013 and 2.07, p = 0.030, respectively), RANKL/OPG ratio was significantly decreased (fold change = 0.50, p = 0.020). No significant differences were found between patients and controls in RANKL and TRAIL expression. Interestingly, TRAIL expression was significantly higher in RA patients with IHD compared to those without IHD (fold change = 1.46, p = 0.033). Moreover, biologic disease-modifying antirheumatic drugs (DMARDs) significantly decreased RANKL expression in RA patients (p = 0.016). Our study supports an important role of OPG and TRAIL in RA. Furthermore, it highlights an effect of biologic DMARDs in the modulation of RANKL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.